Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
South Korea
· Delayed Price · Currency is KRW 441,000
+9,000 (2.08%)
Apr 29, 2026, 2:40 PM KST
Sam Chun Dang Pharm. Revenue
In the year 2025, Sam Chun Dang Pharm. had annual revenue of 231.81B KRW with 9.90% growth. Sam Chun Dang Pharm. had revenue of 66.26B in the quarter ending December 31, 2025, with 20.05% growth.
Revenue
231.81B
Revenue Growth
+9.90%
P/S Ratio
43.34
Revenue / Employee
549.30M
Employees
422
Market Cap
10.05T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 231.81B | 20.88B | 9.90% |
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| Celltrion | 4,162.50B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| HLB Co., Ltd. | 84.17B |
| SK Biopharmaceuticals | 706.74B |
| ABL Bio | 79.35B |
| LigaChem Biosciences | 141.55B |